Chemical Engineering Journal, Journal Year: 2024, Volume and Issue: 498, P. 155323 - 155323
Published: Aug. 30, 2024
Language: Английский
ACS Materials Letters, Journal Year: 2025, Volume and Issue: unknown, P. 884 - 890
Published: Feb. 7, 2025
Language: Английский
Citations
4
Nanomedicine, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 14
Published: Feb. 18, 2025
Aim To develop a glycerol modified liposomes to effectively deliver active agents into posterior segment of the eye for management uveitis.
Language: Английский
Citations
4
Heliyon, Journal Year: 2025, Volume and Issue: 11(2), P. e41881 - e41881
Published: Jan. 1, 2025
Anterior eye disorders including dry syndrome, keratitis, chemical burns, and trauma have varying prevalence rates in the world. Classical dosage forms based-topical ophthalmic drugs are popular treatments for managing corneal diseases. However, current of ocular can be associated with major challenges such as short retention time presence barriers. Developing alternative therapeutic methods is required to overcome drug bioavailability from Nanocarriers platforms promising candidates administration an adjustable manner. This paper briefly introduces advantages, disadvantages, characteristics delivery systems treatment Additionally, advanced technologies 3D printing being considered fabricate carriers determine dosages personalized treatment. comprehensive review gathered through multiple databases Google Scholar, PubMed, Web Science. It explores information around "ocular systems'', "nano-based "engineered nanocarriers'', "advanced systems''.
Language: Английский
Citations
2
Antioxidants, Journal Year: 2024, Volume and Issue: 13(1), P. 120 - 120
Published: Jan. 18, 2024
Diabetes mellitus, the most prevalent endocrine disorder, not only impacts retina but also significantly involves ocular surface. contributes to development of dry eye disease and induces morphological functional corneal alterations, particularly affecting nerves epithelial cells. These changes manifest as defects, reduced sensitivity, delayed wound healing, collectively encapsulated in context diabetic keratopathy. In advanced stages this condition, progression ulcers scarring further unfolds, eventually leading opacities. This critical complication hampers vision carries potential for irreversible visual loss. The primary objective review article is offer a comprehensive overview pathomechanisms underlying Emphasis placed on exploring redox molecular pathways responsible aberrant structural observed cornea tear film during diabetes. Additionally, we provide insights into latest experimental findings concerning treatments targeting oxidative stress. endeavor aims enhance our understanding intricate interplay between diabetes complications, offering valuable perspectives future therapeutic interventions.
Language: Английский
Citations
17
Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)
Published: May 8, 2024
Abstract Efficiently removing excess reactive oxygen species (ROS) generated by various factors on the ocular surface is a promising strategy for preventing development of dry eye disease (DED). The currently available drops DED treatment are palliative, short-lived and frequently administered due to short precorneal residence time. Here, we developed nanozyme-based exploiting borate-mediated dynamic covalent complexation between n-FeZIF-8 nanozymes (n-Z(Fe)) poly(vinyl alcohol) (PVA) overcome these problems. resultant formulation (PBnZ), which has dual-ROS scavenging abilities prolonged corneal retention can effectively reduce oxidative stress, thereby providing an excellent preventive effect alleviate DED. In vitro in vivo experiments revealed that PBnZ could eliminate ROS through both its multienzyme-like activity ROS-scavenging borate bonds. positively charged displayed longer time physical adhesion bonds phenyboronic acid PVA or o-diol with mucin. results showed These dual-function provide insights into novel strategies other ROS-mediated inflammatory diseases rationale application nanomaterials clinical settings. Graphical
Language: Английский
Citations
17
Biopolymers, Journal Year: 2024, Volume and Issue: 115(4)
Published: April 5, 2024
Ocular drug delivery is constrained by anatomical and physiological barriers, necessitating innovative solutions for effective therapy. Natural polymers like hyaluronic acid, chitosan, gelatin, alongside synthetic counterparts such as PLGA PEG, have gained prominence their biocompatibility controlled release profiles. Recent strides in polymer conjugation strategies enabled targeted through ligand integration, facilitating tissue specificity cellular uptake. This versatility accommodates combined delivery, addressing diverse anterior (e.g., glaucoma, dry eye) posterior segment macular degeneration, diabetic retinopathy) afflictions. The review encompasses an in-depth exploration of each natural polymer, detailing individual advantages disadvantages ocular delivery. By transcending barriers refining therapeutic precision, these innovations promise to reshape the management eye diseases.
Language: Английский
Citations
11
International Journal of Pharmaceutics, Journal Year: 2024, Volume and Issue: 658, P. 124192 - 124192
Published: May 3, 2024
Ocular delivery is the most challenging aspect in field of pharmaceutical research. The major hurdle for controlled drugs to eye includes physiological static barriers such as complex layers cornea, sclera and retina which restrict drug from permeating into anterior posterior segments eye. Recent years have witnessed inventions conventional nanocarrier shown considerable enhancement delivering small large molecules across dynamic challenges associated with systems include limited contact time inadequate ocular bioavailability resulting solution drainage, tear turnover, dilution or lacrimation. To this end, various bioactive-based nanosized carriers including liposomes, ethosomes, niosomes, dendrimer, nanogel, nanofibers, lenses, nanoprobes, selenium nanobells, nanosponge, polymeric micelles, silver nanoparticles, gold nanoparticles among others been developed circumvent limitations dosage forms. These nanocarriers achieve enhanced permeation retention prolong release tissue due their better adherence. surface charge size (10–1000 nm) are important key factors overcome barriers. Various deliver active therapeutic timolol maleate, ampicillin, natamycin, voriconazole, cyclosporine A, dexamethasone, moxifloxacin, fluconazole treatment diseases. Taken together, a nutshell, book chapter provides comprehensive perspective on numerous facets special focus bioactive nanocarrier-based approaches, difficulties constraints involved fabrication nanocarriers. This also detailed invention applications ophthalmic therapeutics.
Language: Английский
Citations
11
Small Structures, Journal Year: 2024, Volume and Issue: unknown
Published: Nov. 11, 2024
Topical instillation of cyclosporin A (an anti‐inflammatory drug) is clinically recommended as the first‐line treatment for dry eye disease. Nevertheless, it suffers from poor ocular drug retention and cannot comprehensively address corneal dryness‐related symptoms such oxidative stress, angiogenesis, neurodegeneration. Inspired by nanotechnology‐mediated material/biological interactions, in this study, a highly adhesive metallic nanoplatform with an urchin‐like structure designed topical quercetin administration therapy. The gold nanostructures most pronounced branch lengths exhibit strongest cytoadhesion bioadhesion capabilities, which significantly enhance nano‐urchins 150‐fold at 7 days post‐instillation compared smooth‐surfaced nanoparticles. In rabbit model dryness, single‐dose nanoformulation (high quercetin‐functionalized (NU‐Q(H))) demonstrated remarkable efficacy stimulating tear production (30‐fold improvement), inhibiting inflammatory IL‐6 expression (49‐fold attenuating pathological angiogenesis (32‐fold promoting nerve regeneration (18‐fold improvement) to high nanoparticles (NP‐Q(H)). particular, integrity surface, film, meibomian gland restored levels similar those healthy rabbits. These findings suggest promising potential nanobiomaterial structural engineering developing nanomedicines long‐acting eye‐drop formulations disease applications.
Language: Английский
Citations
11
International Journal of Nanomedicine, Journal Year: 2024, Volume and Issue: Volume 19, P. 2691 - 2708
Published: March 1, 2024
Purpose: Patients afflicted with dry eye disease (DED) experience significant discomfort. The underlying cause of DED is the excessive accumulation ROS on ocular surface. Here, we investigated nitrogen doped-graphene quantum dots (NGQDs), known for their ROS-scavenging capabilities, as a treatment DED. Methods: NGQDs were prepared by using citric acid and urea precursors through hydrothermal method. antioxidant abilities evaluated through: scavenging both extracellular intracellular, regulating nuclear factor-erythroid 2-related factor (Nrf2) pathway human corneal epithelial cells (HCECs) transcription inflammation related genes. Furthermore, modified Arg-Gly-Asp-Ser (RGDS) peptides to obtain RGDS@NGQDs. In vivo , RGDS@NGQDs suspended in 0.1% Pluronic F127 (w/v) delivered drops scopolamine hydrobromide-induced mouse model. Preclinical efficacy was compared healthy DPBS treated mice. Results: These demonstrated pronounced properties, efficiently neutralizing free radicals activating intracellular Nrf2 pathway. vitro studies revealed that H 2 O -exposed HCECs induced preservation cell viability. Additionally, there reduction inflammation-associated To prolong residence time NGQDs, they further RGDS create drops. exhibited superior activity even at low concentrations (10 μg/mL). Subsequent notably mitigated symptoms model, primarily reducing levels. Conclusion: Our findings underscore enhanced benefits achieved modifying GQDs doping peptide tethering. Importantly, our novel formulation effectively ameliorated symptoms, thereby representing therapeutic management. Keywords: disease, antioxidant, doped graphene dots,
Language: Английский
Citations
10
Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)
Published: May 9, 2024
Abstract Background Dry Eye Disease (DED) is a prevalent multifactorial ocular disease characterized by vicious cycle of inflammation, oxidative stress, and mitochondrial dysfunction on the surface, all which lead to DED deterioration impair patients’ quality life social functioning. Currently, anti-inflammatory drugs have shown promising efficacy in treating DED; however, such are associated with side effects. The bioavailability less than 5% owing factors as rapid tear turnover presence corneal barrier. This calls for investigations overcome these challenges drug administration. Results A novel hierarchical action liposome nanosystem (PHP-DPS@INS) was developed this study. In terms delivery, PHP-DPS@INS nanoparticles (NPs) overcame surface transport barrier adopting strategy “ocular electrostatic adhesion-lysosomal site-directed escape”. therapy, achieved targeting antioxidant effects through SS-31 peptide, exerted an effect loading insulin reduce inflammatory metabolites. Ultimately, synergistic “anti-inflammation-antioxidation-mitochondrial function restoration” breaks DED. demonstrated remarkable cellular uptake, lysosomal escape, vitro. Targeted metabolomics analysis revealed that effectively normalized elevated level proinflammatory metabolite fumarate vitro hypertonic model DED, thereby reducing levels key (IL-1β, IL-6, TNF-α). Additionally, strongly inhibited reactive oxygen species (ROS) production facilitated structural repair. vivo, treatment significantly enhanced adhesion duration permeability mice, improving bioavailability. It also restored secretion, suppressed damage, reduced inflammation mice. Moreover, it favorable safety profiles both vivo. Conclusion summary, study successfully comprehensive management transmission disrupted dry eye pathogenesis. pioneered regulation metabolites conditions, presenting safe, efficient, innovative therapeutic other diseases.
Language: Английский
Citations
10